The purpose of this clinical research study is to establish the dose of verinurad combined with allopurinol 300 mg once daily that will elicit the desired response; ie, reduction in urinary albumin to creatinine ratio (UACR) at 6 months.
View Brochure With Details About This Study
View Patient Letter For This Study
Click Here For More Information
Click Here For Information About Study Sponsor